Clinical trials: Fibromyalgia
Fibromyalgia
The Role of Ribose in Patients Diagnosed With Fibromyalgia
The purose of this research study is to determine the potential benefit of D-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.
- Trial name
- NCT00566514
- Testing
- D-ribose, dextrose
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bioenergy Life Science, Inc.
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Fibromyalgia
Study of Milnacipran for the Treatment of Fibromyalgia
Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system.
- Trial name
- NCT00098124
- Testing
- milnacipran hydrochloride
- Where
- 80 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Forest Laboratories
Fibromyalgia
Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome
The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
- Trial name
- NCT00424892
- Testing
- Desvenlafaxine Sustained Release
- Where
- 59 sites in United States
- Volunteers
- 600 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Fibromyalgia
Study Evaluating the Efficacy of DVS-233 in Fibromyalgia
The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.
- Trial name
- NCT00301431
- Testing
- DVS-233
- Where
- 59 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Fibromyalgia
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.
- Trial name
- NCT00190866
- Testing
- Duloxetine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Fibromyalgia
A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia
This is a multicentre, randomized, double-blind, placebo controlled, parallel group exploratory study to investigate the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in female subjects.
- Trial name
- NCT00377039
- Testing
- AD 337
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Sosei
Fibromyalgia
Duloxetine Versus Placebo in the Treatment of FMS
To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.
- Trial name
- NCT00233025
- Testing
- Duloxetine
- Where
- 34 sites in United States, Germany and 4 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Fibromyalgia
Duloxetine Versus Placebo for Fibromyalgia
The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with fibromyalgia.
- Trial name
- NCT00489073
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Eli Lilly and Company
Fibromyalgia
A Study of Duloxetine in the Treatment of Fibromyalgia
This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.
- Trial name
- NCT00125892
- Testing
- duloxetine
- Where
- 27 sites in Argentina, Australia and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company